4-(1,1-二甲基-戊基)-吗啉 | 100535-25-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 中文名称: 4-(1,1-二甲基-戊基)-吗啉
• 英文名称: 4-(1,1-dimethyl-pentyl)-morpholine
• 英文别名: 4-(1,1-Dimethyl-pentyl)-morpholin；4-(2-Methylhexan-2-yl)morpholine
• CAS: 100535-25-9
• 化学式: C₁₁H₂₃NO
• 分子量: 185.31
• InChiKey: WUEVEYWNBQNAFL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  溴丁基-镁 、 2-methyl-2-(morpholin-4-yl)propionitrile 生成 4-(1,1-二甲基-戊基)-吗啉
  参考文献：
  名称：

  Interaction of Certain Grignard Reagents with Nitriles Containing an α-Morpholinyl Substituent¹

  摘要：

  DOI：

  10.1021/ja01580a032

文献信息

• Potassium channel modulators
  申请人：Cadent Therapeutics, Inc.

  公开号：US10774064B2

  公开（公告）日：2020-09-15

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.

  本发明提供了式 (I) 的新型化合物：及其药学上可接受的盐类，它们可用于治疗各种可受钾通道调节影响的疾病、失调或病症。还提供了包含式（I）新型化合物及其药学上可接受的盐的药物组合物，以及将其用于治疗一种或多种与钾通道相关的疾病、失调或病症的方法。
• Synthesis and characterization of Ru alkylidene complexes
  申请人：Umicore AG & Co. KG

  公开号：US11123722B2

  公开（公告）日：2021-09-21

  This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.

  本发明一般涉及烯烃偏合成催化剂化合物、此类化合物的制备、包含此类化合物的组合物、使用此类化合物的方法、包含此类化合物的制造品以及此类化合物在烯烃和烯烃化合物偏合成中的使用。本发明在催化剂、有机合成、聚合物化学以及工业和精细化工领域具有实用性。
• TRICYCLIC HETEROCYCLES AS BET PROTEIN INHIBITORS
  申请人：Incyte Corporation

  公开号：US20170210754A1

  公开（公告）日：2017-07-27

  The present invention relates to tricyclic heterocycles which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
• POTASSIUM CHANNEL MODULATORS
  申请人：Cadent Therapeutics, Inc.

  公开号：US20190218200A1

  公开（公告）日：2019-07-18

  Provided are novel compounds of Formula (I): and pharmaceutically acceptable salts thereof, which are useful for treating a variety of diseases, disorders or conditions which can be affected by potassium channel modulation. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I), pharmaceutically acceptable salts thereof, and methods for their use in treating one or more diseases, disorders or conditions, associated with potassium channels.
• SYNTHESIS AND CHARACTERIZATION OF RU ALKYLIDENE COMPLEXES
  申请人：Umicore AG & Co. KG

  公开号：US20200330970A1

  公开（公告）日：2020-10-22

  This invention relates generally to olefin metathesis catalyst compounds, to the preparation of such compounds, compositions comprising such compounds, methods of using such compounds, articles of manufacture comprising such compounds, and the use of such compounds in the metathesis of olefins and olefin compounds. The invention has utility in the fields of catalysts, organic synthesis, polymer chemistry, and industrial and fine chemicals industry.